Allogeneic Hematopoietic Stem Cell Transplant

BIOLOGICAL3 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Dana-Farber Cancer Institute, Center for International Blood and Marrow Transplant Research

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMultiple MyelomaMyelodysplastic Syndrome

Phase 2

GVAX vs. Placebo for MDS/AML After Allo HSCT

TerminatedNCT01773395

Dana-Farber Cancer InstituteAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome

Start: 2013-01-08End: 2021-11-24Updated: 2022-07-18

Unknown Phase

Busulfan and Cyclophosphamide Followed By ALLO BMT

TerminatedNCT01685411

Masonic Cancer Center, University of MinnesotaAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2013-01-31End: 2020-02-10Updated: 2021-04-13

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

RecruitingNCT03127761

Center for International Blood and Marrow Transplant ResearchMultiple Myeloma

Start: 2017-07-25End: 2028-04-30Target: 544Updated: 2023-08-30

Related Papers

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

Blood Advances2021-11-2220 citations